DURHAM, N.C., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (DOVA) today announced that Dr. David Zaccardelli, President & Chief Executive Officer, will present company overviews at two upcoming investor conferences:
- H.C. Wainwright 21st Annual Global Investment Conference on Monday, September 9, 2019 at 12:30 p.m. ET in New York, NY.
- Ladenburg Thalmann 2019 Healthcare Conference on Tuesday, September 24, 2019 at 2:30 p.m. ET in New York, NY.
A live audio webcast of each event will be available via the "Investor Relations" page of the Dova website, www.dova.com. Please log on through Dova's website approximately 10 minutes before the scheduled start times. A replay of the webcast will be archived on Dova's website for 90 days following the call.
About Dova Pharmaceuticals, Inc.
Dova is a pharmaceutical company focused on acquiring, developing, and commercializing drug candidates for diseases where there is a high unmet need, with an initial focus on addressing thrombocytopenia. Dova’s proprietary pipeline includes one commercial product, DOPTELET®, for the treatment of thrombocytopenia in adult patients with chronic liver disease scheduled to undergo a procedure and the treatment of thrombocytopenia in adults with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. For more information, visit www.Dova.com.
Mark W. Hahn
Chief Financial Officer